Park Circle Company’s Anika Therapeutics ANIK Stock Holding History

Park Circle Company’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,000	Closed	-$434K	–	85
2017 Q1	$434K	Hold	10,000	–	–	0.27%	49
2016 Q4	$490K	Hold	10,000	–	–	0.32%	47
2016 Q3	$479K	Hold	10,000	–	–	0.33%	47
2016 Q2	$537K	Hold	10,000	–	–	0.39%	42
2016 Q1	$447K	Buy	+10,000	New	+$406K	0.34%	43

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Park Circle Company's ANIK Position: Q2 2017 in Review

Park Circle Company sold out of Anika Therapeutics (ANIK) in Q2 2017, closing a stake of 10,000 shares — an estimated $434K sold.

Park Circle Company first reported a position in ANIK in Q1 2016 and held it in 5 quarters. The position peaked at $537K in Q2 2016. 159 funds tracked by Wall St. Rank hold ANIK as of Q2 2017.

Park Circle Company reported no remaining Anika Therapeutics position as of Q2 2017 after selling out during the quarter.
Park Circle Company sold 10,000 Anika Therapeutics shares in Q2 2017, an estimated $434K.
Park Circle Company first reported a position in Anika Therapeutics in Q1 2016 and held it in 5 quarters.
Park Circle Company's Anika Therapeutics position peaked at $537K in Q2 2016.
159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2017.

Based on Park Circle Company's 13F filing for Q2 2017, filed 8 Aug 2017.